Clinical Excellence Queensland

# **Queensland Clinical Guidelines**

Translating evidence into best clinical practice

# Maternity and Neonatal **Clinical Guideline**

Guideline Supplement: Term prelabour rupture of membranes (PROM)





### Acknowledgement

The Department of Health acknowledges the Traditional Custodians of the lands, waters and seas across the State of Queensland on which we work and live. We also acknowledge First Nations peoples in Queensland are both Aboriginal Peoples and Torres Strait Islander Peoples and pay respect to the Aboriginal and Torres Strait Islander Elders past, present and emerging.

#### **Table of Contents**

1	Introduction	3
1.	.1 Funding	3
1.	.2 Conflict of interest	3
1.	.3 Development process	3
1.	.4 Summary of changes	3
2	Methodology	4
2	2.1 Topic identification	4
2	2.2 Scope	4
2	2.3 Clinical questions	4
2	2.4 Search strategy	5
	2.4.1 Keywords	5
2	2.5 Consultation	6
2	2.6 Endorsement	6
2	2.7 Citation	6
3	Levels of evidence	7
3.	3.1 Summary recommendations	7
4	Implementation	8
4.	l.1 Guideline resources	8
4.	l.2 Suggested resources	8
4.	I.3 Implementation measures	8
	4.3.1 QCG measures	8
	4.3.2 Hospital and Health Service measures	8
	4.3.3 Implications for implementation	8
4.	l.4 Quality measures	9
4.	l.5 Areas for future research	9
4.	l.6 Safety and quality	10
Ref	ferences	18
Ack	knowledgements	18
List	t of Tables	
Tab	ole 1. Summary of change	3
	ole 2. Scope framework	
	ole 3. Basic search strategy	
	ble 4. Major guideline development processes	
	ole 5. Summary recommendationsble 6. NSQHS Standard 1	
	ble 7. Clinical quality measures	
	ble 8. NSQHS	

© State of Queensland (Queensland Health) 2023



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute Queensland Clinical Guidelines, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en">https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en</a>

For further information contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email <a href="mailto:Guidelines@health.qld.gov.au">Guidelines@health.qld.gov.au</a>, For permissions beyond the scope of this licence contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email <a href="mailto:pofficer@health.qld.gov.au">pofficer@health.qld.gov.au</a>

### 1 Introduction

This document is a supplement to the Queensland Clinical Guideline: *Term prelabour rupture of membranes (PROM)*. It provides supplementary information regarding guideline development, makes summary recommendations, suggests measures to assist implementation and quality activities and summarises changes (if any) to the guideline since original publication. Refer to the guideline for abbreviations, acronyms, flow charts and acknowledgements.

# 1.1 Funding

The development of this guideline was funded by Healthcare Improvement Unit, Queensland Health. Consumer representatives were paid a standard fee. Other working party members participated on a voluntary basis.

### 1.2 Conflict of interest

Declarations of conflict of interest were sought from working party members as per the Queensland Clinical Guidelines *Conflict of Interest* statement. No conflict of interest was identified.

### 1.3 Development process

This version of the guideline followed the QCG Peer review process.

## 1.4 Summary of changes

Queensland clinical guidelines are reviewed every 5 years or earlier if significant new evidence emerges. Table 1 provides a summary of changes made to the guidelines since original publication.

Table 1. Summary of change

Publication date Endorsed by:	Identifier	Summary of major change
December 2018  Statewide Maternity and Neonatal Clinical Network (QLD)	MN18.47-V1-R23	First publication
December 2023  QLD Maternity and  Neonatal Clinical Network	MN23.47-V2-R28	Peer Review:  Section: Outcomes of active management compared to expectant management  Data updated Flow amended Flowcharts aligned with text Elements of Queensland Clinical Guideline: Standard care removed Formatting and references updated

# 2 Methodology

Queensland Clinical Guidelines (QCG) follows a rigorous process of guideline development. This process was endorsed by the Queensland Health Patient Safety and Quality Executive Committee in December 2009. The guidelines are best described as 'evidence informed consensus guidelines' and draw from the literature, the evidence base of existing national and international guidelines and the expert opinion of the working party.

# 2.1 Topic identification

The topic was identified as a priority by the Queensland Maternity and Neonatal Clinical Network at a forum in 2009.

# 2.2 Scope

The scope of the guideline was determined using the following framework.

Table 2. Scope framework

Scope framewo	Scope framework		
Population	Women with a live singleton, cephalic fetus equal to or greater than 37+0 weeks gestation, who have suspected prelabour rupture of membranes		
Purpose	<ul> <li>Identify relevant evidence related to:</li> <li>Diagnosis, assessment and management of PROM</li> </ul>		
Outcome	<ul> <li>Support evidence informed:         <ul> <li>Identification of PROM</li> <li>Management of pregnant women following PROM</li> </ul> </li> <li>Discussion with pregnant women about the risks and benefits of management options following PROM</li> </ul>		
Routine antenatal, intrapartum and postpartum care     Risk factors for PROM     Management of:     Early onset Group B Streptococcal disease     Chorioamnionitis     Aspects of care included in the Queensland Clinical Guidelines:     Standard care     Preterm prelabour rupture of membranes (PPROM)     Early onset Group B Streptococcal disease     Induction of labour			

### 2.3 Clinical questions

The following clinical questions were generated to inform the guideline scope and purpose:

- How is PROM diagnosed?
- What are the risks and benefits of expectant versus active management?
- What is best practice care during expectant management?
- When is active management recommended?
- When are antibiotics recommended for PROM?

### 2.4 Search strategy

A search of the literature was conducted during May 2023—July 2023. A further search was conducted in August 2023. The QCG search strategy is an iterative process that is repeated and amended as guideline development occurs (e.g. if additional areas of interest emerge, areas of contention requiring more extensive review are identified or new evidence is identified). All guidelines are developed using a basic search strategy. This involves both a formal and informal approach.

Table 3. Basic search strategy

Step		Consideration	
1.	Review clinical guidelines developed by other reputable groups relevant to the clinical speciality	<ul> <li>This may include national and/or international guideline writers, professional organisations, government organisations, state based groups.</li> <li>This assists the guideline writer to identify:         <ul> <li>The scope and breadth of what others have found useful for clinicians and informs the scope and clinical question development</li> <li>Identify resources commonly found in guidelines such as flowcharts, audit criteria and levels of evidence</li> <li>Identify common search and key terms</li> <li>Identify common and key references</li> </ul> </li> </ul>	
2.	Undertake a foundation search using key search terms	Construct a search using common search and key terms identified during Step 1 above Search the following databases PubMed CINAHL Medline Cochrane Central Register of Controlled Trials EBSCO Embase Studies published in English less than or equal to 5 years previous are reviewed in the first instance. Other years may be searched as are relevant to the topic Save and document the search Add other databases as relevant to the clinical area	
3.	Develop search word list for each clinical question	<ul> <li>This may require the development of clinical sub-questions beyond those identified in the initial scope.</li> <li>Using the foundation search performed at Step 2 as the baseline search framework, refine the search using the specific terms developed for the clinical question</li> <li>Save and document the search strategy undertaken for each clinical question</li> </ul>	
4.	Other search strategies	<ul> <li>Search the reference lists of reports and articles for additional studies</li> <li>Access other sources for relevant literature         <ul> <li>Known resource sites</li> <li>Internet search engines</li> <li>Relevant textbooks</li> </ul> </li> </ul>	

### 2.4.1 Keywords

The following keywords were used in the basic search strategy: rupture of membranes, fetal membranes, ROM, PROM, prelabour rupture of membranes, waters break, active management, expectant management.

Other keywords may have been used for specific aspects of the guideline.

### 2.5 Consultation

Major consultative and development processes occurred between September 2023 and October 2023.

Table 4. Major guideline development processes

Process	Activity		
Decision for peer review	<ul> <li>A review of the guideline scope, clinical questions and current literature was undertaken in May 2023. Areas of clinical practice change were identified</li> <li>Clinical leads         <ul> <li>Reviewed the previous scope and version of the guideline</li> <li>Reviewed identified areas of clinical practice change</li> <li>Confirmed aspects of the guideline for update and new inclusions</li> <li>Reached consensus agreement that a peer review process was appropriate</li> </ul> </li> </ul>		
Consultation	<ul> <li>Expert clinicians and a consumer representative were identified by the clinical leads and invited to peer review the updated guideline in July 2023</li> <li>All invited members accepted</li> </ul>		

### 2.6 Endorsement

The guideline was endorsed by the:

- Queensland Clinical Guidelines Steering Committee in December 2023
- Queensland Maternity and Neonatal Clinical Network in December 2023

#### 2.7 Citation

The recommended citation of Queensland Clinical Guidelines is in the following format:

Queensland Clinical Guidelines. [Insert Guideline Title]. Guideline No. [Insert Guideline Number]. Queensland Health. [Insert Year of Publication]. Available from: www.health.qld.gov.au/qcg.

#### **EXAMPLE:**

Queensland Clinical Guidelines. Normal birth. Guideline No. MN17.25-V3-R22. Queensland Health 2017. Available from: <a href="www.health.qld.gov.au/qcg">www.health.qld.gov.au/qcg</a>.

# 3 Levels of evidence

Summary recommendations were informed by:

- Review of literature
- Expertise and experience of clinical leads and working party
- Statewide consultation
- Established Queensland Clinical Guidelines development process

# 3.1 Summary recommendations

Summary recommendations and levels of evidence are outlined in Table 5. Summary recommendations.

Table 5. Summary recommendations

Recon	nmendations	Strength of recommendation
1.	Avoid digital examination unless immediate induction is planned as this increases the rate of infection	Consensus
2.	In the absence of maternal or fetal indications, routine antibiotics for PROM are not recommended <sup>1</sup>	Consensus
3.	If membranes have been ruptured for 18 hours or more, recommend intrapartum Group B streptococcus (GBS) prophylaxis <sup>2</sup>	Consensus
4.	Advise women of the increased risk of infection after 24 hours of PROM <sup>3</sup>	Consensus

# 4 Implementation

This guideline is applicable to all Queensland public and private maternity facilities. It can be downloaded in Portable Document Format (PDF) from www.health.gld.gov.au/gcg

#### 4.1 Guideline resources

The following guideline components are provided on the website as separate resources:

- Flowchart: Summary of prelabour rupture of membranes at term
- Education resource: Term prelabour rupture of membranes
- Knowledge assessment: Term prelabour rupture of membranes
- Parent information: Term prelabour rupture of membranes

## 4.2 Suggested resources

During the development process stakeholders identified additional resources with potential to complement and enhance guideline implementation and application. The following resources have not been sourced or developed by QCG but are suggested as complimentary to the guideline:

- Procedures supporting clinical examination of the woman with term PROM including abdominal palpation, sterile speculum examination, collection of swabs
- Identify eligibility criteria for expectant management at home including distance of home from hospital
- Procedures for the use of point of care tests for the presence of amniotic fluid

### 4.3 Implementation measures

Suggested activities to assist implementation of the guideline are outlined below.

#### 4.3.1 QCG measures

- Notify Chief Executive Officer and relevant stakeholders
- Monitor emerging new evidence to ensure guideline reflects contemporaneous practice
- Capture user feedback
- Record and manage change requests

### 4.3.2 Hospital and Health Service measures

Initiate, promote and support local systems and processes to integrate the guideline into clinical practice, including:

- Hospital and Health Service (HHS) Executive endorse the guidelines and their use in the HHS and communicate this to staff
- Promote the introduction of the guideline to relevant health care professionals
- Support education and training opportunities relevant to the guideline and service capabilities
- Align clinical care with guideline recommendations
- Undertake relevant implementation activities as outlined in the Guideline implementation checklist available at www.health.qld.gov.au/qcg

### 4.3.3 Implications for implementation

The following areas may have implications for local implementation of the guideline recommendations. It is suggested they be considered for successful guideline implementation.

- Economic considerations including opportunity costs
- Human resource requirements including clinician skill mix and scope of practice
- Clinician education and training
- Equipment and consumables purchase and maintenance
- Consumer acceptance
- Model of care and service delivery

## 4.4 Quality measures

Auditing of guideline recommendations and content assists with identifying quality of care issues and provides evidence of compliance with the National Safety and Quality Health Service (NSQHS)Standards<sup>4</sup> [Refer to Table 6. NSQHS Standard 1]. Suggested audit and quality measures are identified in Table 7. Clinical quality measures.

Table 6. NSQHS Standard 1

NSQHS Standard 1: Clinical governance		
Clinical performance and effectiveness		
Criterion 1.27:	Actions required:	
Evidence based care	<ul> <li>a. Provide clinicians with ready access to best-practice guidelines, integrated care pathways, clinical pathways and decision support tools relevant to their clinical practice</li> </ul>	
Evidence based care	b. Support clinicians to use the best available evidence, including relevant clinical care standards developed by the Australian Commission on Safety and Quality in Health Care	

The following clinical quality measures are suggested:

Table 7. Clinical quality measures

No	Audit criteria	Guideline section
1.	Proportion of women with term PROM who are provided with information about the risks and benefits of expectant and active management	Management options
2.	Proportion of women with term PROM greater than 18 hours who receive intrapartum GBS prophylaxis	Antibiotics

### 4.5 Areas for future research

During development the following areas where identified as having limited or poor quality evidence to inform clinical decision making. Further research in these areas may be useful.

 Differences in maternal and neonatal outcomes (including maternal experience) between inpatient and at home expectant care

# 4.6 Safety and quality

In conjunction with the Queensland Clinical Guideline: <u>Standard care</u><sup>5</sup>, implementation of this guideline provides evidence of compliance with the National Safety and Quality Health Service Standards.<sup>4</sup>

Table 8. NSQHS

NSQHS Criteria	Actions required	☑ Evidence of compliance	
NSQHS Standard 1: Clinical governance			
Patient safety and quality systems Safety and quality systems are integrated with governance processes to enable organisations to actively manage and improve the safety and quality of health care for patients.	Diversity and high risk groups 1.15 The health service organisation: a. Identifies the diversity of the consumers using its services b. Identifies groups of patients using its services who are at higher risk of harm c. Incorporates information on the diversity of its consumers and higher-risk groups into the planning and delivery of care	<ul> <li>✓ Assessment and care appropriate to the cohort of patients is identified in the guideline</li> <li>✓ High risk groups are identified in the guideline</li> <li>✓ The guideline is based on the best available evidence</li> </ul>	
Clinical performance and effectiveness The workforce has the right qualifications, skills and supervision to	Evidence based care  1.27 The health service organisation has processes that: a. Provide clinicians with ready access to best-practice guidelines, integrated care pathways, clinical pathways and decision support tools relevant to their clinical practice b. Support clinicians to use the best available evidence, including relevant clinical care standards developed by the Australian Commission on Safety and Quality in Health Care	<ul> <li>Queensland Clinical Guidelines is funded by Queensland Health to develop clinical guidelines relevant to the service line to guide safe patient care across Queensland</li> <li>The guideline provides evidence-based and best practice recommendations for care</li> <li>The guideline is endorsed for use in Queensland Health facilities.</li> <li>A desktop icon is available on every Queensland Health computer desktop to provide quick and easy access to the guideline</li> </ul>	
provide safe, high-quality health care to patients.	Performance management 1.22 The health service organisation has valid and reliable performance review processes that: a. Require members of the workforce to regularly take part in a review of their performance b. Identify needs for training and development in safety and quality c. Incorporate information on training requirements into the organisation's training system	☑ The guideline has accompanying educational resources to support ongoing safety and quality education for identified professional and personal development. The resources are freely available on the internet <a href="http://www.health.qld.gov.au/qcg">http://www.health.qld.gov.au/qcg</a>	

NSQHS Criteria	Actions required	☑ Evidence of compliance	
NSQHS Standard 1: Clinical governance			
Patient safety and quality systems Safety and quality systems are integrated with governance processes to enable organisations to actively manage and improve the safety and quality of health care for patients.	Policies and procedures 1.7 The health service organisation uses a risk management approach to: a. Set out, review, and maintain the currency and effectiveness of, policies, procedures and protocols b. Monitor and take action to improve adherence to policies, procedures and protocols c. Review compliance with legislation, regulation and jurisdictional requirements	<ul> <li>☑ QCG has established processes to review and maintain all guidelines and associated resources</li> <li>☑ Change requests are managed to ensure currency of published guidelines</li> <li>☑ Implementation tools and checklist are provided to assist with adherence to guidelines</li> <li>☑ Suggested audit criteria are provided in guideline supplement</li> <li>☑ The guidelines comply with legislation, regulation and jurisdictional requirements</li> </ul>	
NSQHS Standard 2: Partnering with Co			
Health literacy Health service organisations communicate with consumers in a way that supports effective partnerships.	Communication that supports effective partnerships  2.8 The health service organisation uses communication mechanisms that are tailored to the diversity of the consumers who use its services and, where relevant, the diversity of the local community  2.9 Where information for patients, carers, families and consumers about health and health services is developed internally, the organisation involves consumers in its development and review  2.10 The health service organisation supports clinicians to communicate with patients, carers, families and consumers about health and health care so that:  a. Information is provided in a way that meets the needs of patients, carers, families and consumers  b. Information provided is easy to understand and use  c. The clinical needs of patients are addressed while they are in the health service organisation  d. Information needs for ongoing care are provided on discharge	<ul> <li>☑ Consumer consultation was sought and obtained during the development of the guideline. Refer to the acknowledgement section of the guideline for details</li> <li>☑ Consumer information is developed to align with the guideline and included consumer involvement during development and review</li> <li>☑ The consumer information was developed using plain English and with attention to literacy and ease of reading needs of the consumer</li> </ul>	
Partnering with consumers in organisational design and governance Consumers are partners in the design and governance of the organisation.	Partnerships in healthcare governance planning, design, measurement and evaluation 2.11 The health service organisation: a. Involves consumers in partnerships in the governance of, and to design, measure and evaluate, health care b. Has processes so that the consumers involved in these partnerships reflect the diversity of consumers who use the service or, where relevant, the diversity of the local community 2.14 The health service organisation works in partnership with consumers to incorporate their views and experiences into training and education for the workforce	<ul> <li>☑ Consumers are members of guideline working parties</li> <li>☑ The guideline is based on the best available evidence</li> <li>☑ The guidelines and consumer information are endorsed by the QCG and Queensland Statewide Maternity and Neonatal Clinical Network Steering Committees which includes consumer membership</li> </ul>	

NSQHS Criteria	Actions required	☑ Evidence of compliance
NSQHS Standard 2: Partnering with Co	onsumers	
Partnering with consumers in their own care	Healthcare rights and informed consent  2.4 The health service organisation ensures that its informed consent processes comply with legislation and best practice  2.5 The health service organisation has processes to identify:  a. The capacity of a patient to make decisions about their own care  b. A substitute decision-maker if a patient does not have the capacity to make decisions for themselves	<ul> <li>☑ This guideline and consumer information provides information for consumers to make informed decisions</li> <li>☑ This guideline promotes informed consent</li> </ul>
Patients are partners in their own care to the extent that they choose	Shared decisions and planning care  2.6 The health service organisation has processes for clinicians to partner with patients and/or their substitute decision-maker to plan, communicate, set goals, and make decisions about their current and future care  2.7 The health service organisation supports the workforce to form partnerships with patients and carers so that patients can be actively involved in their own care	<ul> <li>☑ Consumer information is available for this guideline</li> <li>☑ Consumers are members of guideline working parties</li> </ul>
NSQHS Standard 3:Infection prevention	on and control systems	
Clinical governance and quality improvement to prevent and control healthcare-associated infections, and support antimicrobial stewardship  Systems are in place to support and promote prevention and control of healthcare-associated infections, and improve antimicrobial stewardship.	Integrating clinical governance 3.1The workforce uses the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for healthcare-associated infections and antimicrobial stewardship b. Managing risks associated with healthcare-associated infections and antimicrobial stewardship	<ul> <li>☑ The guideline provides evidence-based and best practice recommendations for care</li> <li>☑ Recommendations for use of antimicrobials are evidence based</li> </ul>
Infection prevention and control systems Patients presenting with, or with risk factors for, infection or colonisation with an organism of local, national or global significance are identified promptly, and receive the necessary management and treatment.	Standard and transmission-based precautions 3.6 Clinicians assess infection risks and use transmission-based precautions based on the risk of transmission of infectious agents, and consider: a. Patients' risks, which are evaluated at referral, on admission or on presentation for care, and re-evaluated when clinically required during care	<ul> <li>☑ The guideline provides evidence-based and best practice recommendations for care</li> <li>☑ Assessment and care appropriate to the cohort of patients is identified in the guideline</li> <li>☑ High risk groups are identified in the guideline if applicable</li> </ul>
Antimicrobial stewardship Systems are implemented for safe and appropriate prescribing and use of antimicrobials as part of an antimicrobial stewardship program	Antimicrobial stewardship 3.15 The health service organisation has an antimicrobial stewardship program that: a. Includes an antimicrobial stewardship policy b. Provides access to, and promotes the use of, current evidence-based Australian therapeutic guidelines and resources on antimicrobial prescribing	<ul> <li>☑ The guideline provides evidence-based and best practice recommendations for care</li> <li>☑ Recommendations for use of antimicrobials are evidence based</li> <li>☑ If applicable, Australian therapeutic guidelines and resources were used to develop guideline recommendations</li> </ul>

NSQHS Criteria	Actions required	☑ Evidence of compliance	
NSQHS Standard 4: Medication safety			
Clinical governance and quality improvement to support medication management Organisation-wide systems are used to support and promote safety for procuring, supplying, storing, compounding, manufacturing, prescribing, dispensing, administering and monitoring the effects of medicines	Integrating clinical governance 4.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for medication management b. Managing risks associated with medication management c. Identifying training requirements for medication management	☑ The guideline provides current evidence based recommendations about medication	
NSQHS Standard 5: Comprehensive ca	are		
Clinical governance and quality improvement to support comprehensive care Systems are in place to support clinicians to deliver comprehensive care	Integrating clinical governance 5.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for comprehensive care b. Managing risks associated with comprehensive care c. Identifying training requirements to deliver comprehensive care Partnering with consumers 5.3 Clinicians use organisational processes from the Partnering with Consumers Standard when providing comprehensive care to: a. Actively involve patients in their own care b. Meet the patient's information needs c. Share decision-making	<ul> <li>☑ The guideline has accompanying educational resources to support ongoing safety and quality education for identified professional and personal development. The resources are freely available on the internet <a href="http://www.health.qld.gov.au/qcg">http://www.health.qld.gov.au/qcg</a></li> <li>☑ The guideline provides evidence-based and best practice recommendations for care</li> <li>☑ Consumer information is developed for the guideline</li> </ul>	

NSQHS Criteria	Actions required	☑ Evidence of compliance			
NSQHS Standard 6: Communicating fo	NSQHS Standard 6: Communicating for safety				
Clinical governance and quality improvement to support effective communication Systems are in place for effective and coordinated communication that supports the delivery of continuous and safe care for patients.	Integrating clinical governance 6.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures to support effective clinical communication b. Managing risks associated with clinical communication c. Identifying training requirements for effective and coordinated clinical communication Partnering with consumers 6.3 Clinicians use organisational processes from the Partnering with Consumers Standard to effectively communicate with patients, carers and families during high-risk situations to: a. Actively involve patients in their own care b. Meet the patient's information needs c. Share decision-making Organisational processes to support effective communication 6.4 The health service organisation has clinical communications processes to support effective communication when: a. Identification and procedure matching should occur b. All or part of a patient's care is transferred within the organisation, between multidisciplinary teams, between clinicians or between organisations; and on discharge c. Critical information about a patient's care, including information on risks, emerges or changes	<ul> <li>☑ Requirements for effective clinical communication by clinicians are identified</li> <li>☑ The guideline provides evidence-based and best practice recommendations for communication between clinicians</li> <li>☑ The guideline provides evidence-based and best practice recommendations for communication with patients, carers and families</li> <li>☑ The guideline provides evidence-based and best practice recommendations for discharge planning and follow –up care</li> </ul>			
Communication of critical information Systems to effectively communicate critical information and risks when they emerge or change are used to ensure safe patient care.	Communicating critical information 6.9 Clinicians and multidisciplinary teams use clinical communication processes to effectively communicate critical information, alerts and risks, in a timely way, when they emerge or change to: a. Clinicians who can make decisions about care b. Patients, carers and families, in accordance with the wishes of the patient 6.10 The health service organisation ensures that there are communication processes for patients, carers and families to directly communicate critical information and risks about care to clinicians	<ul> <li>☑ Requirements for effective clinical communication of critical information are identified</li> <li>☑ Requirements for escalation of care are identified</li> </ul>			

NSQHS Criteria	Actions required	☑ Evidence of compliance		
NSQHS Standard 6: Communicating for safety (continued)				
Correct identification and procedure matching Systems to maintain the identity of the patient are used to ensure that the patient receives the care intended for them.	Correct identification and procedure matching 6.5 The health service organisation: a. Defines approved identifiers for patients according to best- practice guidelines b. Requires at least three approved identifiers on registration and admission; when care, medication, therapy and other services are provided; and when clinical handover, transfer or discharge documentation is generated	☑ Requirements for safe and for correct patient identification are identified		
Communicating at clinical handover Processes for structured clinical handover are used to effectively communicate about the health care of patients.	Clinical handover 6.7 The health service organisation, in collaboration with clinicians, defines the: a. Minimum information content to be communicated at clinical handover, based on best-practice guidelines b. Risks relevant to the service context and the particular needs of patients, carers and families c. Clinicians who are involved in the clinical handover 6.8 Clinicians use structured clinical handover processes that include: a. Preparing and scheduling clinical handover b. Having the relevant information at clinical handover c. Organising relevant clinicians and others to participate in clinical handover d. Being aware of the patient's goals and preferences e. Supporting patients, carers and families to be involved in clinical handover, in accordance with the wishes of the patient f. Ensuring that clinical handover results in the transfer of responsibility and accountability for care	☑ The guideline acknowledges the need for local protocols to support transfer of information, professional responsibility and accountability for some or all aspects of care		

NSQHS Criteria	Actions required	☑ Evidence of compliance		
NSQHS Standard 7: Blood management				
Clinical governance and quality improvement to support blood management Organisation-wide governance and quality improvement systems are used to ensure safe and high-quality care of patients' own blood, and to ensure that blood product requirements are met.	Integrating clinical governance 7.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for blood management b. Managing risks associated with blood management c. Identifying training requirements for blood management	☑ The guideline provides evidence-based and best practice recommendations for use of blood products		
Prescribing and clinical use of blood and blood products The clinical use of blood and blood products is appropriate, and strategies are used to reduce the risks associated with transfusion.	Optimising and conserving patients' own blood 7.4 Clinicians use the blood and blood products processes to manage the need for, and minimise the inappropriate use of, blood and blood products by: a. Optimising patients' own red cell mass, haemoglobin and iron stores b. Identifying and managing patients with, or at risk of, bleeding c. Determining the clinical need for blood and blood products, and related risks Prescribing and administering blood and blood products 7.6 The health service organisation supports clinicians to prescribe and administer blood and blood products appropriately, in accordance with national guidelines and national criteria	<ul> <li>✓ The guideline provides evidence-based and best practice recommendations for use of blood products</li> <li>✓ The guideline is consistent with recommendations of national guidelines</li> </ul>		

NSQHS Criteria	Actions required	☑ Evidence of compliance		
NSQHS Standard 8: Recognising and responding to acute deterioration				
Clinical governance and quality improvement to support recognition and response systems Organisation-wide systems are used to support and promote detection and recognition of acute deterioration, and the response to patients whose condition acutely deteriorates.	Integrating clinical governance 8.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for recognising and responding to acute deterioration b. Managing risks associated with recognising and responding to acute deterioration c. Identifying training requirements for recognising and responding to acute deterioration Partnering with consumers 8.3 Clinicians use organisational processes from the Partnering with Consumers Standard when recognising and responding to acute deterioration to: a. Actively involve patients in their own care b. Meet the patient's information needs c. Share decision-making Recognising acute deterioration 8.4 The health service organisation has processes for clinicians to detect acute physiological deterioration that require clinicians to: a. Document individualised vital sign monitoring plans b. Monitor patients as required by their individualised monitoring plan c. Graphically document and track changes in agreed observations to detect acute deterioration over time, as appropriate for the patient	<ul> <li>☑ The guideline is consistent with National Consensus statements recommendations</li> <li>☑ The guideline recommends use of tools consistent with the principles of recognising and responding to clinical deterioration</li> <li>☑ Consumer information is developed for the guideline</li> </ul>		

### References

- 1. Wojcieszek A, Stock Q, Flenady V. Antibiotics for prelabour rupture of membranes at or near term. Cochrane Database of Systematic Reviews. 2014 [cited 2023 May 2]; Issue 10. Art. No.: CD001807. DOI:10.1002/14651858.CD001807.pub2.
- 2. Ohlsson A, Shah V. Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Systematic Reviews. [Internet]. 2014 [cited 2023 May 2]; (6):CD007467 DOI:10.1002/14651858.CD007467.pub4.
- 3. Seaward PG, Hannah ME, Myhr TL, Farine D, Ohlsson A, Wang EE, et al. International multicentre term prelabor rupture of membranes study: evaluation of predictors of clinical chorioamnionitis and postpartum fever in patients with prelabor rupture of membranes at term. American Journal of Obstetrics and Gynecology 1997;177(5):1024-9.
- 4. Australian Commission on Safety and Quality in Health Care. National safety and quality health service standards [Internet]. 2017 [2023 May 2]. Available from: <a href="http://www.safetyandquality.gov.au">http://www.safetyandquality.gov.au</a>.
- 5. Queensland Clinical Guidelines. Standard care. Guideline No. MN18.50-V1-R23. [Internet]. Queensland Health. 2018. [cited 2023 May 2]. Available from: https://www.health.gld.gov.au/qcg.

# Acknowledgements

Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process particularly:

#### **Working Party Clinical Leads**

Ms Beth Shorter, Registered Midwife, Midwifery Group Practice, Cairns Hospital and Health Service Associate Professor Thangeswaran Rudra, Senior Staff Specialist, Obstetrics and Gynaecology, Royal Brisbane and Women's Hospital

#### **QCG Program Officer**

Ms Emily Holmes

#### Working party membership

Dr Elize Bolton, Clinical Director, Bundaberg Hospital and Health Service

Ms Lynne Buetow, Midwife, Acting Midwifery Educator, Royal Brisbane and Women's Hospital

Ms Eileen Cooke, Consumer Representative, Preterm Infants Parents Association Inc. (PIPA)

Ms Helen Coxhead, Lecturer Nursing and Midwifery, James Cook University

Dr David Freidin, Staff Specialist, Obstetrics and Gynaecology, Royal Brisbane and Women's Hospital

Dr Siew Goh, Senior Medical Officer, Dalby Hospital and Health Service

Dr Leigh Grant, Director of Obstetrics and Gynaecology, Mackay Hospital

Ms Meredith Lovegrove, Midwifery Educator, Gladstone Hospital

Dr Saliya Ovitigalage, Staff Specialist, Hervey Bay Hospital

Ms Angela Swift, Clinical Midwife Consultant, Royal Brisbane and Women's Hospital

#### **Queensland Clinical Guidelines Team**

Professor Rebecca Kimble, Director Ms Jacinta Lee, Manager Ms Stephanie Sutherns, Clinical Nurse Consultant Ms Cara Cox, Clinical Nurse Consultant Ms Emily Holmes, Clinical Nurse Consultant Ms Jacqueline Plazina, Clinical Nurse Consultant Steering Committee